-
公开(公告)号:HRP20090143T3
公开(公告)日:2009-04-30
申请号:HRP20090143
申请日:2009-03-10
Applicant: SOLVAY PHARM BV
Inventor: KOOPMAN THEODORUS S M , KOSTER HENDRIK J , AMSTERDAM PETER H VAN , FEENSTRA ROELOF W , VERHAGE MARINUS , MCCREARY ANDREW C , HESSELINK MAYKE B
IPC: C07D263/58 , A61K31/423 , A61P25/00 , C07D295/24
Abstract: The present invention relates to N-oxides of certain piperazine and piperidine derivatives and to methods for the preparation of these compounds. The invention also relates to the use of compounds disclosed herein for the manufacture of a medicament giving a beneficial effect. A beneficial effect is disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. The invention also relates to the use of a compound of the invention for the manufacture of a medicament for treating or preventing a disease or condition. More particularly, the invention relates to a new use for the treatment of a disease or condition disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. In embodiments of the invention specific compounds disclosed herein are used for the manufacture of a medicament useful in the treatment of CNS-disorders, in particular the treatment of anxiety disorders, including generalized anxiety disorder and panic disorder, obsessive compulsive disorder, aggression, addiction (including craving), depression, autism, vertigo, schizophrenia and other psychotic disorders, Parkinson's disease and disturbances of cognition and memory. The compounds have the general formula (1) wherein the symbols have the meanings given in the specification.
-
公开(公告)号:HRP20090015T3
公开(公告)日:2009-02-28
申请号:HRP20090015
申请日:2009-01-13
Applicant: SOLVAY PHARM BV
Inventor: FEENSTRA ROELOF W , STOIT AXEL , TERPSTRA JAN-WILLEM , PRAS-RAVES MARIA L , MCCREARY ANDREW C , VLIET BERNARD J VAN , HESSELINK MAYKE B , KRUSE CORNELIS G , SCHARRENBURG G J M VAN
IPC: A61K31/423 , A61P25/00 , C07D263/58
Abstract: The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and partial agonism on dopamine -D2 receptors. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The compounds have the general formula (1) wherein the symbols have the meanings given in the specification.
-
公开(公告)号:ES2311245T3
公开(公告)日:2009-02-01
申请号:ES05850037
申请日:2005-12-06
Applicant: SOLVAY PHARM BV
Inventor: FEENSTRA ROELOF W , STOIT AXEL , TERPSTRA JAN-WILLEM , PRAS-RAVES MARIA L , MCCREARY ANDREW C , VAN VLIET BERNARD J
IPC: A61K31/423 , A61P25/00 , C07D263/58 , C07D413/12
Abstract: Compuestos de fórmula general (1): Z-T-Ar (1) donde: Z es un fragmento de fórmula general (2) (Ver fórmula) donde: X = S u O, R1 es H, alquilo(C1-C6), CF3, CH2CF3, OH u O-alquilo(C1-C6), R2 es H, alquilo(C1-C6), halógeno o ciano, R3 es H ó alquilo(C1-C6), R4 es H, alquilo(C1-C6) opcionalmente substituído con un átomo de halógeno, T es una cadena de 2-7 átomos de carbono saturada o no saturada, donde un átomo de carbono puede estar reemplazado con un átomo de nitrógeno, opcionalmente substituído con un grupo alquilo(C1 - C3), CF3 ó CH2CF3, o un átomo de oxígeno o un átomo de azufre, estando dicha cadena opcionalmente substituida con uno o más substituyentes seleccionados del grupo que consiste en alquilo(C1-C3), alcoxi(C1-C3), halógeno, ciano, trifluorometilo, OCF3, SCF3, OCHF2 y nitro, Ar se selecciona entre los grupos: (Ver fórmula) donde dicho grupo Ar además puede estar opcionalmente substituído con uno o más substituyentes seleccionados del grupo que consiste en alquilo(C1-C3), alcoxi(C1-C3), halógeno, ciano, trifluorometilo, OCF3, SCF3, OCHF2 y nitro, y donde en dichos grupos Ar que contienen un anillo de cinco miembros, el doble enlace del anillo de cinco miembros puede ser saturado, y tautómeros, estereoisómeros y N-óxidos de los mismos, así como las sales, hidratos y solvatos farmacológicamente aceptables de dichos compuestos de fórmula (1) y sus tautómeros, estereoisómeros y N-óxidos.
-
公开(公告)号:DE602005010902D1
公开(公告)日:2008-12-18
申请号:DE602005010902
申请日:2005-12-06
Applicant: SOLVAY PHARM BV
Inventor: FEENSTRA ROELOF W , STOIT AXEL , TERPSTRA JAN-WILLEM , PRAS-RAVES MARIA L , MCCREARY ANDREW C , VAN VLIET BERNARD J , HESSELINK MAYKE B , KRUSE CORNELIS G , VAN SCHARRENBURG G J M
IPC: A61K31/423 , A61P25/00 , C07D263/58
Abstract: The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and partial agonism on dopamine -D2 receptors. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The compounds have the general formula (1) wherein the symbols have the meanings given in the specification.
-
公开(公告)号:BRPI0518862A2
公开(公告)日:2008-12-09
申请号:BRPI0518862
申请日:2005-12-06
Applicant: SOLVAY PHARM BV
Inventor: FEENSTRA ROELOF W , STOIT AXEL , TERPSTRA JAN-WILLEM , PRAS-RAVES MARIA L , MCCREARY ANDREW C , VLIET BERNARD J VAN , HESSELINK MAYKE B , KRUSE CORNELIS G , SCHARRENBURG GUSTAAF J M
IPC: A61K31/423 , A61P25/00 , C07D263/58 , C07D413/12
-
公开(公告)号:BRPI0518621A2
公开(公告)日:2008-12-02
申请号:BRPI0518621
申请日:2005-12-06
Applicant: SOLVAY PHARM BV
Inventor: FEENSTRA ROELOF W , STOIT AXEL , TERPSTRA JAN-WILLEM , PRAS-RAVES MARIA L , MCCREARY ANDREW C , VAN VLIET BERNARD J , HESSELINK MAYKE B , KRUSE CORNELIS G , VAN SCHARRENBURG GUSTAAF J M
IPC: A61K31/423 , A61P25/00 , C07D263/58
-
公开(公告)号:BRPI0518613A2
公开(公告)日:2008-11-25
申请号:BRPI0518613
申请日:2005-12-06
Applicant: SOLVAY PHARM BV
Inventor: FEENSTRA ROELOF W , STOIT AXEL , TERPSTRA JAN-WILLEM , PRAS-RAVES MARIA L , VLIET BERNARD J VAN , HESSELINK MAYKE B , KRUSE CORNELIS G , MCCREARY ANDREW C , VAN SCHARRENBURG GUSTAAF J M
IPC: A61K31/423 , A61P25/00 , C07D263/58 , C07D413/12
Abstract: The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and partial agonism on dopamine -D2 receptors. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The compounds have the general formula (1) wherein the symbols have the meanings given in the specification.
-
48.
公开(公告)号:PT1827427E
公开(公告)日:2008-11-03
申请号:PT05850037
申请日:2005-12-06
Applicant: SOLVAY PHARM BV
Inventor: FEENSTRA ROELOF W , STOIT AXEL , TERPSTRA JAN-WILLEM , PRAS-RAVES MARIA L , MCCREARY ANDREW C , VLIET BERNARD J VAN , HESSELINK MAYKE B , KRUSE CORNELIS G , SCHARRENBURG GUSTAAF J M VAN
IPC: A61K31/423 , A61P25/00 , C07D263/58 , C07D413/12
-
公开(公告)号:DE602005008471D1
公开(公告)日:2008-09-04
申请号:DE602005008471
申请日:2005-12-06
Applicant: SOLVAY PHARM BV
Inventor: FEENSTRA ROELOF W , STOIT AXEL , TERPSTRA JAN-WILLEM , PRAS-RAVES MARIA L , MCCREARY ANDREW C , VAN VLIET BERNARD J , HESSELINK MAYKE B , KRUSE CORNELIS G , VAN SCHARRENBURG GUSTAAF J M
IPC: A61K31/423 , A61P25/00 , C07D263/58 , C07D413/12
Abstract: The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and partial agonism on dopamine -D2 receptors. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The compounds have the general formula (1) wherein the symbols have the meanings given in the specification.
-
公开(公告)号:ZA200704211B
公开(公告)日:2008-05-28
申请号:ZA200704211
申请日:2007-05-23
Applicant: SOLVAY PHARM BV
Inventor: FEENSTRA ROELOF W , JAN-WILLEM TERPSTRA , MCCREARY ANDREW C , HESSELINK MAYKE B , VAN SCHARRANBURG GUSTAAF J M , AXEL STOIT , PRAS-RAVES MARIA L , VAN VLIET BERNARD J , KRUSE CORNELIS G
IPC: A61K20090101 , A61P20090101 , C07D20090101
Abstract: The invention relates to a group of novel phenylpiperazine derivatives with a dual mode of action: serotonin reuptake inhibition and partial agonism on dopamine-D2 receptors. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The compounds have the general formula (1): wherein the symbols have the meanings given in the specification, and tautomers, stereoisomers and N-oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of said compounds of formula (1) and its tautomers, stereoisomers and N-oxides.
-
-
-
-
-
-
-
-
-